Top-line data from a Phase II study combining Regulus Therapeutics Inc.'s RG-101 with approved direct-acting antiviral drugs for hepatitis C indicate that adding a microRNA therapeutic to a DAA – particularly Gilead Sciences Inc.'s Harvoni – may finally bring the concept of four-week curative treatment for HCV to reality.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?